Risperidone for psychosis of Alzheimer's disease and mixed dementia: Results of a double-blind, placebo-controlled trial

Abstract

Objective: To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of Alzheimer's disease (AD) and mixed dementia (MD) in a subset of nursing-home residents who had dementia and agression and who were participating in a randomized placebo-controlled trial of risperidone for agreesion. Method: This post-hoc analysis included only patients diagnosed with AD or MD with psychosis, defined by a score of ≥ 2 on any item of the Behavioral Pathology of Alzheimer's Disease (BEHAVE-AD) psychosis subscale at both screening and baseline. Co-primary efficacy endpoints were changes in scores on BEHAVE-AD psychosis subscale and Clinical Global Impression of Change (CGI-C). Results..